Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is character...
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for pat...
Top Cities for Wet Age-Related Macular Degeneration Clinical Trials
Wet Age-Related Macular Degeneration clinical trials are recruiting across 14 cities. Here are the cities with the most active studies:
About Wet Age-Related Macular Degeneration
Wet age-related macular degeneration is the advanced form of AMD where abnormal blood vessels grow under the retina and leak fluid or blood. It can cause rapid vision loss if untreated. Treatment involves regular anti-VEGF injections that can stabilize or improve vision.
Clinical trials are advancing new treatments for wet age-related macular degeneration. Currently, 2 studies are recruiting a combined 648 participants across the United States. Research is being conducted by 2 organizations including AbbVie, Neuracle Genetics, Inc.
2026 Wet Age-Related Macular Degeneration Research Landscape
As of March 2026, the wet age-related macular degeneration clinical trial landscape includes 2 actively recruiting studies across 14 cities in the United States. These studies are collectively seeking 648 participants, with an average enrollment target of 324 per study.
Research is being led by 2 different organizations, including AbbVie, Neuracle Genetics, Inc.
Geographically, wet age-related macular degeneration trials are most concentrated in Toronto, Ontario (2 trials); Phoenix, Arizona (1 trial); Sun City, Arizona (1 trial); Little Rock, Arkansas (1 trial); Beverly Hills, California (1 trial) and 7 other cities.
Featured Wet Age-Related Macular Degeneration Studies
Highlighted recruiting studies for wet age-related macular degeneration, selected by enrollment size and research scope.
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living ...
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
Frequently Asked Questions About Wet Age-Related Macular Degeneration Clinical Trials
Are there wet age-related macular degeneration clinical trials near me?
Yes, there are 2 wet age-related macular degeneration clinical trials currently recruiting across 14+ cities in the United States, including Toronto, Ontario; Phoenix, Arizona; Sun City, Arizona. Browse the studies above to find one at a location convenient for you.
How do I join a wet age-related macular degeneration clinical trial?
To join a wet age-related macular degeneration clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are wet age-related macular degeneration clinical trials free?
Yes, participation in wet age-related macular degeneration clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of wet age-related macular degeneration treatments are being studied?
Current wet age-related macular degeneration clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 2 research organizations.
Is it safe to participate in wet age-related macular degeneration clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov